Relmada Therapeutics, Inc.'s (RLMD) CEO Sergio Traversa on Q1 2022 Results - Earnings Call Transcript

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET

Company Participants

Tim McCarthy - LifeSci Advisors, Investor Relations
Sergio Traversa - Chief Executive Officer
Maged Shenouda - Chief Financial Officer

Conference Call Participants

Andrew Tsai - Jefferies
Andrea Tan - Goldman Sachs
Yatin Suneja - Guggenheim Partners
Marc Goodman - SVB Leerink
Vamil Divan - Mizuho Securities
Matt Hershenhorn - Oppenheimer

Operator

Ladies and gentlemen, thank you for standing by. And welcome to the Relmada Therapeutics, Inc. First Quarter 2022 Earnings Call. During the presentation all participants will be in listen-only mode. Afterwards, we will conduct a question-and-answer session. [Operator Instructions]

As a reminder, this conference is being recorded, Thursday, May 5, 2022. I would now like to turn the conference over to Tim McCarthy, LifeSci Advisors. Please go ahead.

Tim McCarthy

Thank you, Ingrid, and thank you all for joining us this afternoon. With me on today’s call our Chief Executive Officer, Sergio Traversa; and Chief Financial Officer, Maged Shenouda.

This afternoon, Relmada issued a news release providing a business update announcing financial results for the three months ended March 31, 2022 and filed its quarterly report on Form 10-Q with the SEC.

Please note that certain information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, Relmada’s management team will be making forward-looking statements.

Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company’s business. These forward-looking statements are qualified by the cautionary statements contained in Relmada’s press release issued today, and the company’s SEC filings, including in the annual report on Form 10-K for the year ended December 30, 2021, and subsequent filings.